ClinicalTrials.gg
CompletedNCT01813474Updated Jan 16, 2018Results posted

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

A Phase 1 interventional study of olaparib in Cancer and Advanced Solid Malignancies, sponsored by AstraZeneca. Completed at 3 sites in Japan. Open to participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-01-16.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
20 Years to 130 Years
Sex
All
01

Study summary

The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of olaparib will be investigated.

Read the detailed description

MTD - maximum tolerated dose

02

Conditions studied

  • Cancer
  • Advanced Solid Malignancies

Browse trials for

Keywords

  • Cancer
  • Tumour
  • Solid Malignancies
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 23 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with advanced solid who are to standard therapies or for which no standard therapy exists.
  • Subjects who have overall good overall general condition.
  • Subjects who agree to hospitalisation from starting olaparib to multiple dose period at day 15.
  • Evidence of non-childbearing status for women of , or status.
  • Subjects who have at least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI at baseline and follow up visits

Exclusion criteria

Exclusion Criteria:

  • Subjects who received any previous treatment with a PARP (poly adenosine diphosphate-ribose polymerase) inhibitor, including olaparib.
  • Subjects receiving inhibitors of (cytochrome P450 3A4).
  • Subjects with symptomatic uncontrolled .
  • Subjects with myelodysplastic syndrome/acute myeloid leukaemia.
  • Subjects with a known to olaparib or any of the of the product.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    olaparib tablet monotherapy

    olaparib tablet

    Drug: olaparib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. This was recorded if it happend from the start dose to 30 days after the last of study drug.

    Time frame: From the start dose to 30 days after the last dose of study drug

Secondary outcomes

  1. Number of Participants With Dose Limiting Toxicities

    Dose Limiting Toxicities were defined as study specific events that is determined to be possibly or probably related to olaparib (as determined by the investigator) and occurring during the first cycle of treatment (28 days after the first dose), irrespective of whether the toxicity resolved.

    Time frame: From the start dose to 28 days after the first dose of study drug

  2. Cmax Following Single Dosing

    Time frame: Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose

  3. Cmax Following Multiple Dosing

    Time frame: Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose

  4. Tmax Following Single Dosing

    Time frame: Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose

  5. Tmax Following Multiple Dosing

    Time frame: Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose

  6. AUC Following Single Dosing

    Time frame: Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose

  7. AUC at Steady State Following Multiple Dosing

    Time frame: Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose

07

Results

Posted Dec 12, 2017

Participant flow

First patient enrolled on 25 March 2013. Last patient enrolled on 31 October 2013. Data cut off on 31 July 2014.

Participant flow — Overall Study
Milestone200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part300 mg Bid, Expansion Part
Started4712
Completed101
Not completed3711
Withdrew: Withdrawal by subject001
Withdrew: Adverse event110
Withdrew: Lack of efficacy269
Withdrew: Death001

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. This was recorded if it happend from the start dose to 30 days after the last of study drug.

Time frame:
From the start dose to 30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Adverse Events
Participants200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part300 mg Bid, Expansion Part
At least 1 Adverse Events (AE)4710
At least 1 AE of CTCAE Grade 3 or higher131
At least 1 Serious Adverse Events (SAE)100
SecondaryNumber of Participants With Dose Limiting Toxicities

Dose Limiting Toxicities were defined as study specific events that is determined to be possibly or probably related to olaparib (as determined by the investigator) and occurring during the first cycle of treatment (28 days after the first dose), irrespective of whether the toxicity resolved.

Time frame:
From the start dose to 28 days after the first dose of study drug
Reported as:
Number · Participants
Number of Participants With Dose Limiting Toxicities
Participants200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part
Number of Participants With Dose Limiting Toxicities00
SecondaryCmax Following Single Dosing
Time frame:
Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose
Reported as:
Geometric mean · μg/mL
Cmax Following Single Dosing
μg/mL200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part
Cmax Following Single Dosing6.697 ± 95.697.743 ± 34.76
SecondaryCmax Following Multiple Dosing
Time frame:
Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose
Reported as:
Geometric mean · μg/mL
Cmax Following Multiple Dosing
μg/mL200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part
Cmax Following Multiple Dosing7.668 ± 46.938.434 ± 35.05
SecondaryTmax Following Single Dosing
Time frame:
Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose
Reported as:
Median · hour
Tmax Following Single Dosing
hour200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part
Tmax Following Single Dosing2.00 ± 95.691.98 ± 34.76
SecondaryTmax Following Multiple Dosing
Time frame:
Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose
Reported as:
Median · hour
Tmax Following Multiple Dosing
hour200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part
Tmax Following Multiple Dosing1.50 ± 46.933.00 ± 35.05
SecondaryAUC Following Single Dosing
Time frame:
Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose
Reported as:
Geometric mean · μg*h/mL
AUC Following Single Dosing
μg*h/mL200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part
AUC Following Single Dosing61.97 ± 473.446.21 ± 64.64
SecondaryAUC at Steady State Following Multiple Dosing
Time frame:
Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose
Reported as:
Geometric mean · μg*h/mL
AUC at Steady State Following Multiple Dosing
μg*h/mL200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part
AUC at Steady State Following Multiple Dosing36.50 ± 71.9452.34 ± 68.17

Adverse events

Collected over Through treatment and 30-day follow-up period, an average of about 4 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Bid, Dose Escalation Part—1/4 (25%)4/4 (100%)
300 mg Bid, Dose Escalation Part—0/7 (0%)7/7 (100%)
300 mg Bid, Expansion Part—0/12 (0%)10/12 (83.3%)
Most frequent serious events
Most frequent serious events
Event200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part300 mg Bid, Expansion Part
IleusGastrointestinal disorders1/40/70/12
Most frequent other events
Showing 10 of 51
Most frequent other events
Event200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part300 mg Bid, Expansion Part
NauseaGastrointestinal disorders1/46/73/12
AnaemiaBlood and lymphatic system disorders0/44/72/12
Decreased appetiteMetabolism and nutrition disorders0/44/73/12
White blood cell count decreasedInvestigations0/43/72/12
ConstipationGastrointestinal disorders0/42/74/12
DiarrhoeaGastrointestinal disorders0/42/72/12
DyspepsiaGastrointestinal disorders0/42/71/12
ProteinuriaRenal and urinary disorders0/42/70/12
MalaiseGeneral disorders0/42/72/12
Neutrophil count decreasedInvestigations0/42/72/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part300 mg Bid, Expansion PartTotal
Mean42.0 ± 8.6855.4 ± 8.9857.3 ± 12.4354.1 ± 11.94
Sex: Female, Male
Sex: Female, Male(Participants)200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part300 mg Bid, Expansion PartTotal
Sex — Female44715
Sex — Male0358
Primary tumour location
Primary tumour location(Participants)200 mg Bid, Dose Escalation Part300 mg Bid, Dose Escalation Part300 mg Bid, Expansion PartTotal
Breast1135
Colorectal0011
Lung0123
Peritoneum0011
Pancreas0101
Ovary0224
Uterus1102
Cervix2002
Colon0011
Gastric Antrum0011
Other0112
08

Study locations

3 sites
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Fukuoka-shi, 811-1395, Japan
  • Research Site
    Sapporo-shi, 003-0804, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Aug 2016, 41 months.

Results were first posted in Dec 2017, 1 year 3 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 41 months is close to that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2013
First posted
Mar 19, 2013
StartActual
Mar 25, 2013
Primary completionActual
Aug 31, 2016
CompletionActual
Aug 31, 2016
Results first posted
Dec 12, 2017
Last update
Jan 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01813474
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 19, 2013
Start date
Mar 25, 2013
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016
Results posted
Dec 12, 2017
Last update
Jan 16, 2018

Study contacts

Thomas Morris, M.D.
study director · Global Medicines Development

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion